<DOC>
	<DOCNO>NCT00808639</DOCNO>
	<brief_summary>The purpose research study test effectiveness neoadjuvant dose-dense methotrexate , vinblastine , doxorubicin , cisplatin ( ddMVAC ) combination pegfilgrastim follow radical surgery patient muscle-invasive urothelial carcinoma .</brief_summary>
	<brief_title>Dose-Dense MVAC With Pegfilgrastim Support Subjects With Muscle-Invasive Urothelial Carcinoma</brief_title>
	<detailed_description>- Participants give study infusion schedule treatment cycle . Each treatment cycle last three week . The infusion methotrexate take place first day cycle . Infusions vinblastine , doxorubicin cisplatin take place second day injection pegfilgrastim give third day . - During treatment cycle participant physical exam ask question general health problem might medication may take . - Following completion study treatment , surgery , participant assessment tumor CT scan chest MRI abdomen pelvis . - Following participant surgery , would like keep track medical condition indefinitely , study officially complete . We would like call participant telephone year see .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologic proof urothelial cancer . Patients histologic subtypes eligible long transitional cell carcinoma predominant , exception cluster small cell carcinoma , treat different chemotherapy thus ineligible Patients primary tumor arise bladder urethra eligible clinical T2T4a disease Patients primary tumor arise ureter renal pelvis eligible either grade 3 tumor , radiographic abnormality large enough recognize abnormal mass CT/imaging Evaluation urologist deem acceptable surgical candidate within 3 month registration Adequate physiologic reserve outline protocol Clinical pathologic N1 lymph node involvement ( involvement single lymph node &lt; 2cm great dimension ) eligible . Patients N23 M1 disease ineligible Determination LV function EF &gt; 50 % Women childbearing potential must negative pregnancy test Patients childbearing fatherbearing potential must agree use acceptable form birth control study Patients prior malignancy eligible provide expect outcome prior cancer interfere delivery therapy , assessment response cystectomy specimen 18 year age old Current , recent ( within 3 week ) , plan participation experimental anticancer medication part clinical trial Prior treatment doxorubicin Prior systemic cytoreductive chemotherapy bladder cancer Blood pressure &gt; 160/100 mmHg . Patients whose blood pressure control oral medication eligible NYHA Grade II great congestive heart failure History myocardial infarction unstable angina within 6 month prior study enrollment History stroke transient ischemic attack within 6 month prior study enrollment Clinically significant peripheral vascular disease Evidence bleed diathesis coagulopathy Known history central nervous system brain metastasis Major surgical procedure , significant traumatic injury within 21 day prior Day 1 , anticipation need major surgical procedure course study Lactating woman Patients candidate surgery , unwilling undergo surgery Patients significant fluid collection Known hypersensitivity component cisplatin , methotrexate , vinblastine , doxorubicin pegfilgrastim</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pegfilgrastim</keyword>
	<keyword>MVAC</keyword>
</DOC>